109 related articles for article (PubMed ID: 7812632)
1. Close correlation of the cardioprotective effect of FK409, a spontaneous NO releaser, with an increase in plasma cyclic GMP level.
Kita Y; Sugimoto T; Hirasawa Y; Yoshida K; Maeda K
Br J Pharmacol; 1994 Sep; 113(1):5-6. PubMed ID: 7812632
[TBL] [Abstract][Full Text] [Related]
2. Antianginal effects of FK409, a new spontaneous NO releaser.
Kita Y; Ozaki R; Sakai S; Sugimoto T; Hirasawa Y; Ohtsuka M; Senoh H; Yoshida K; Maeda K
Br J Pharmacol; 1994 Dec; 113(4):1137-40. PubMed ID: 7889266
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409.
Kita Y; Hirasawa Y; Maeda K; Nishio M; Yoshida K
Eur J Pharmacol; 1994 May; 257(1-2):123-30. PubMed ID: 8082692
[TBL] [Abstract][Full Text] [Related]
4. Antiplatelet activities of FK409, a new spontaneous NO releaser.
Kita Y; Hirasawa Y; Yoshida K; Maeda K
Br J Pharmacol; 1994 Oct; 113(2):385-8. PubMed ID: 7834188
[TBL] [Abstract][Full Text] [Related]
5. FK409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty.
Seki J; Nishio M; Kato Y; Motoyama Y; Yoshida K
Atherosclerosis; 1995 Sep; 117(1):97-106. PubMed ID: 8546759
[TBL] [Abstract][Full Text] [Related]
6. Protective effects of FK409, a novel nitric oxide donor, against postischemic myocardial dysfunction in guinea-pig hearts.
Cao Y; Hotta Y; Shioi K; Nagata Y; Kawai N; Ishikawa N
J Cardiovasc Pharmacol; 2001 Oct; 38(4):593-605. PubMed ID: 11588530
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of FK409, a spontaneous nitric oxide releaser, on ischemic acute renal failure in rats.
Matsumura Y; Nishiura M; Deguchi S; Hashimoto N; Ogawa T; Seo R
J Pharmacol Exp Ther; 1998 Dec; 287(3):1084-91. PubMed ID: 9864296
[TBL] [Abstract][Full Text] [Related]
8. Comparison of hemodynamic effects of nitric oxide (NO) donors with different NO-releasing properties in rats.
Kita Y; Hirasawa Y; Kato Y; Ohkubo K; Ohno M; Nishino S; Kato M; Fukuyama S
J Cardiovasc Pharmacol; 1997 Aug; 30(2):223-8. PubMed ID: 9269950
[TBL] [Abstract][Full Text] [Related]
9. Failure of nitric oxide donors to alter arrhythmias induced by acute myocardial ischaemia or reperfusion in anaesthetized rats.
Barnes CS; Coker SJ
Br J Pharmacol; 1995 Jan; 114(2):349-56. PubMed ID: 7881734
[TBL] [Abstract][Full Text] [Related]
10. Effect of FK409, a novel nitric oxide donor, on acute experimental myocardial ischemia.
Isono T; Sato N; Koibuchi Y; Sakai S; Yamamoto T; Ozaki R; Mori J; Kohsaka M; Ohtsuka M
Jpn J Pharmacol; 1993 Jul; 62(3):315-24. PubMed ID: 8411778
[TBL] [Abstract][Full Text] [Related]
11. Effect of nitrovasodilators and inhibitors of nitric oxide synthase on ischaemic and reperfusion function of rat isolated hearts.
du Toit EF; McCarthy J; Miyashiro J; Opie LH; Brunner F
Br J Pharmacol; 1998 Mar; 123(6):1159-67. PubMed ID: 9559900
[TBL] [Abstract][Full Text] [Related]
12. Oral biological activities of spontaneous nitric oxide releasers are accounted for by their nitric oxide-releasing rates and oral absorption manners.
Kita Y; Hirasawa Y; Fukuyama S; Ohkubo K; Kato Y; Takamatsu H; Ohno M; Nishino S; Kato M; Seki J
J Pharmacol Exp Ther; 1996 Feb; 276(2):421-5. PubMed ID: 8632305
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of FK409, a novel nitric oxide donor, on reperfusion injury of rat liver.
Ohmori H; Dhar DK; Nakashima Y; Hashimoto M; Masumura S; Nagasue N
Transplantation; 1998 Sep; 66(5):579-85. PubMed ID: 9753335
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of spontaneous nitric oxide releasers, FK409 and its derivatives.
Fukuyama S; Hirasawa Y; Kato Y; Nishio M; Ohno M; Nishino S; Maeda K; Kato M; Kita Y
J Pharmacol Exp Ther; 1997 Jul; 282(1):236-42. PubMed ID: 9223559
[TBL] [Abstract][Full Text] [Related]
15. Antianginal effects of FR144420, a novel slow nitric oxide-releasing agent.
Hirasawa Y; Sugimoto T; Fukuyama S; Kato Y; Takamatu H; Ohno M; Nishino S; Kato M; Maeda K; Seki J; Kita Y
Eur J Pharmacol; 1996 May; 303(1-2):55-9. PubMed ID: 8804911
[TBL] [Abstract][Full Text] [Related]
16. FR144420, a novel, slow, nitric oxide-releasing agent.
Kita Y; Ohkubo K; Hirasawa Y; Katayama Y; Ohno M; Nishino S; Kato M; Yoshida K
Eur J Pharmacol; 1995 Mar; 275(2):125-30. PubMed ID: 7796846
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of novel nitric oxide donor (FK409) on pulmonary ischemia-reperfusion injury in rats.
Takeyoshi I; Otani Y; Yoshinari D; Kawashima Y; Ohwada S; Matsumoto K; Morishita Y
J Heart Lung Transplant; 2000 Feb; 19(2):185-92. PubMed ID: 10703696
[TBL] [Abstract][Full Text] [Related]
18. Acceleration of nitric oxide (NO) release from FK409, a spontaneous NO releaser, in the presence of sulfhydryl-bearing compounds.
Fukuyama S; Hirasawa Y; Cox D; Koda S; Kita Y
Pharm Res; 1995 Dec; 12(12):1948-52. PubMed ID: 8786971
[TBL] [Abstract][Full Text] [Related]
19. Comparison of antiplatelet effects of FK409, a spontaneous nitric oxide releaser, with those of TRK-100, a prostacyclin analogue.
Hirasawa Y; Nishio M; Maeda K; Yoshida K; Kita Y
Eur J Pharmacol; 1995 Jan; 272(1):39-43. PubMed ID: 7713147
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ischaemic preconditioning in the eNOS overexpressed working mouse heart model.
du Toit EF; Genade S; Carlini S; Moolman JA; Brunner F; Lochner A
Eur J Pharmacol; 2007 Feb; 556(1-3):115-20. PubMed ID: 17157294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
